论文部分内容阅读
目的 :以他唑巴坦 /哌拉西林为试验药 ,泰能为对照药 ,通过随机对照及开放试验 ,评价前者的安全性和有效性。方法 :他唑巴坦 /哌拉西林 4 5g/次 ,静滴 ,q12h～q8h ,泰能 1 0g/次 ,静滴 ,q12h～q8h,疗程 7～14天 ,重症者适当延长。以中、重度急性细菌性感染者为试验对象。结果 :试验组完成 2 8例 (包括开放组 10例 ) ,对照组 2 0例。试验组临床有效率 89 2 9% ,对照组 95 0 0 % ;不同细菌感染患者试验组有效率为 91 67% ,对照组者为 94 4 4% ,无显著性差异 (P >0 0 5 )。试验组与对照组细菌阳性率为 85 71%与 90 0 0 % ,细菌清除率和阴转率为 88 0 0 %与 94 4 4% (P >0 0 5 ) ,细菌产酶率均在 70 %以上。 4 2株致病菌中革兰阴性菌 3 0株 ,革兰阳性菌 12株 ,4株耐哌拉西林者对他唑巴坦 /哌拉西林敏感 ,其中 3株产酶 ,且他唑巴坦 /哌拉西林联合后 ,使哌拉西林敏感菌更为敏感。细菌对他唑巴坦 /哌拉西林的敏感率与对哌拉西林及阿莫西林 /克拉维酸者有显著性差异(P <0 0 5 ) ,且它对革兰阳性球菌及大部分革兰阴性菌的MIC值较其他四种抗生素低 ,试验组 2 8例未出现不良反应 ,对照组 1例出现恶心头晕 ,自行缓解 ,不良反应发生率为 5 0 0 % (1/ 2 0 )。结论 :他唑巴坦 /哌拉西林抗菌谱广 ,抗菌活性强
OBJECTIVE: Tacrolimus and piperacillin were used as the test drugs, and Tianeng as the reference drug. The safety and efficacy of the former were evaluated by randomized controlled trials and open trials. Methods: tazobactam / piperacillin 45g / time, intravenous drip, q12h ~ q8h, Thai energy 10g / intravenous infusion, q12h ~ q8h, 7 to 14 days course of treatment, severe patients were appropriately extended. To moderate and severe acute bacterial infections were tested. Results: There were 28 cases (including 10 cases in open group) and 20 cases in control group. The clinical effective rate was 89.29% in the experimental group and 95.0% in the control group. The effective rate was 91.67% in the experimental group and 94.4% in the control group, with no significant difference (P> 0.05) . The positive rates of bacteria in the test group and the control group were 85 71% and 90 0 0%, the bacterial clearance rates and the negative conversion rates were 88 0% and 94 4 4% (P 0 05) %the above. Among the 42 pathogenic bacteria, 30 strains of Gram-negative bacteria, 12 strains of Gram-positive bacteria and 4 strains resistant to piperacillin were sensitive to tazobactam / piperacillin, of which 3 strains were producing enzymes and tazobact Tan / piperacillin combined, the piperacillin-sensitive bacteria more sensitive. The sensitivity rates of bacteria to tazobactam / piperacillin were significantly different from those of piperacillin and amoxicillin / clavulanic acid (P <0 05), and their sensitivity to gram-positive cocci and most of the leathers The MIC value of blue-negative bacteria was lower than that of the other four antibiotics. No adverse reactions were found in 28 cases in the experimental group. One case in the control group developed nausea and dizziness and relieved itself. The incidence of adverse reactions was 500% (1/20). Conclusion: Tazobactam / piperacillin antibacterial spectrum is wide, strong antibacterial activity